Argos Therapeutics, Inc. (NASDAQ:ARGS) shares gapped down prior to trading on Wednesday . The stock had previously closed at $0.17, but opened at $0.16. Argos Therapeutics shares last traded at $0.15, with a volume of 4221100 shares.

The company has a debt-to-equity ratio of -1.46, a current ratio of 2.29 and a quick ratio of 2.29.

A hedge fund recently bought a new stake in Argos Therapeutics stock. Wasatch Advisors Inc. bought a new position in Argos Therapeutics, Inc. (NASDAQ:ARGS) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 665,831 shares of the biopharmaceutical company’s stock, valued at approximately $120,000. Wasatch Advisors Inc. owned about 1.21% of Argos Therapeutics at the end of the most recent reporting period. 18.35% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY NOTICE: This report was posted by Daily Political and is the sole property of of Daily Political. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.dailypolitical.com/2017/12/15/argos-therapeutics-args-shares-gap-down-to-0-16.html.

About Argos Therapeutics

Argos Therapeutics, Inc (Argos) is an immuno-oncology company. The Company is focused on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases based on its technology platform called Arcelis. The Company’s Arcelis technology platform utilizes biological components from a patient’s own cancer cells or virus to generate individualized immunotherapies.

Receive News & Ratings for Argos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Argos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.